Alzheimer's disease, a profoundly impactful neurodegenerative condition, manifests as the progressive deterioration of memory and cognitive functions. Studies have shown that memory decline is associated with a decrease in the rapid transmission of excitatory signals between neurons. The limited research on the positive impact of AMPA receptor modulation has prompted the exploration of Ampakine compounds. Ampakines enhance long-term potentiation (LTP) by activating receptors, which exists in a crucial role in memory preservation. The ability of ampakine compounds to bind to AMPA receptors and increase the expression of neurotrophic factors, such as BDNF, is believed to mitigate LTP impairment. Recent studies have demonstrated that certain ampakine compounds can enhance consciousness and memory storage by promoting the production of various neurotrophins, particularly BDNF and NGF. Previous research has shown that neurotrophins contribute to synaptogenesis, the formation of new connections between neurons, primarily
through dendritic spines. Increasing synaptogenesis via dendritic spines positively impacts signal transmission and retention by strengthening neuronal connections. This review highlights the potential of ampakine compounds such as pesampator and hydroflumetazide to enhance synaptic interactions, alleviate symptoms of Alzheimer's disease, and specifically address memory loss through their effects on neurotrophins.
TDK-2022-11285
TDK-2022-11285
Primary Language | English |
---|---|
Subjects | Pharmaceutical Sciences |
Journal Section | Reviews |
Authors | |
Project Number | TDK-2022-11285 |
Early Pub Date | December 29, 2023 |
Publication Date | December 31, 2023 |
Submission Date | November 9, 2023 |
Acceptance Date | December 28, 2023 |
Published in Issue | Year 2023 Volume: 1 Issue: 3 |